Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WBF-010
- Development stage
- Unknown
- Lead developer
- Pendulum Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
WBF-010 is a **probiotic formulation** investigated for metabolic support in people with type 2 diabetes, composed of select strains of beneficial bacteria that are intended to modulate the gut microbiome and influence metabolic outcomes. In a randomized, placebo-controlled trial in type 2 diabetes, WBF-010 showed **no statistically significant improvement in glycemic control, glucose area under the curve (AUC)**, or glycated hemoglobin (A1c) compared to placebo over 12 weeks. The formulation was **well-tolerated with no safety signals**, and its use did not lead to meaningful changes in inflammatory markers or major disturbances in the gut microbiota profile. Modest increases in stool short-chain fatty acids like butyrate were observed, but these changes did not correlate with clinical endpoints in this study. WBF-010 was developed as part of the early clinical pipeline for microbiome-based therapies targeting metabolic diseases, but lacks robust evidence of efficacy.
- Brand names
- WBF-010WBF010WBF 010
- Other names
- WBF-010WBF010WBF 010
Beyond the preview
Go deeper on WBF-010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WBF-010.